Unannounced to prescribers or patients, Novo Nordisk have changed the manufacturing process of their human insulins from enzymatic modification of pig insulin (emp) to direct biosynthesis of genetically engineered yeast cells (pyr). The preservative for Human Actrapid insulin has also been changed from phenol to meta-cresol. No warning of this change was sent to pharmacists, doctors, diabetes specialists or patients.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.